Single-agent bevacizumab or lomustine versus a combination...

The Lancet Oncology 2014 / 08 Vol. 15; Iss. 9

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Taal, Walter, Oosterkamp, Hendrika M, Walenkamp, Annemiek M E, Dubbink, Hendrikus J, Beerepoot, Laurens V, Hanse, Monique C J, Buter, Jan, Honkoop, Aafke H, Boerman, Dolf, de Vos, Filip Y F, Dinjens,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
15
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(14)70314-6
Date:
August, 2014
File:
PDF, 358 KB
english, 2014
Conversion to is in progress
Conversion to is failed